Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1

Journal of Immunology

Volumn 161, Issue 5, 1998, Pages 2099-2105

  Petersson, Max ^a,d   Charo, Jehad ^a   Salazar Onfray, Flavio ^a   Noffz, Gabriele ^b   Mohaupt, Mariette ^b   Qin, Zhihai ^b   Klein, George ^a   Blankenstein, Thomas ^b   Kiessling, Rolf ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; H2 ANTIGEN; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; ASCITES TUMOR; CONTROLLED STUDY; GENETIC TRANSDUCTION; LYMPHOMA CELL LINE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; RETROVIRUS; T CELL LYMPHOMA;

ANIMALS; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; CYTOTOXICITY, IMMUNOLOGIC; H-2 ANTIGENS; INTERLEUKIN-10; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MICE; MICE, INBRED A; MICE, INBRED C57BL; TUMOR CELLS, CULTURED;

EID: 0032167547     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. MacNeil, I. A., T. Suda, K. W. Moore, T. R. Mosmann, and A. Zlotnik. 1990. IL-10, a novel growth cofactor for mature and immature T cells. J. Immunol. 145:4167.
2. Chen, W. F., and A. Zlotnik. 1991. IL-10: a novel cytotoxic T cell differentiation factor. J. Immunol. 147:528.
3. Fiorentino, D. F., A. Zlotnic, P. Viera, T. R. Mosmann, M. Howard, K. W. Moore, and A. O'Garra. 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146:3444.
4. Taga, K. G., and G. Tosato. 1992. IL-10 inhibits T cell proliferation and IL-2 production. J. Immunol. 148:1143.
5. de Waal-Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. de Vries. 1991. IL-10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II MHC expression. J. Exp. Med. 174:915.
6. Ding, L., P. S. Linsley, L.-Y. Huang, R. R. Germain, and E. M. Shevach. 1993. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 151:1224.
7. Gazzinelli, R. T., I. P. Oswald, S. L. James, and A. Sher. 1992. IL-10 inhibits parasite killing and nitric oxide production by IFN-γ-activated macrophages. J. Immunol. 148:1792.
8. Matsuda, M., F. Salazar, M. Petersson, G. Masucci, J. Hansson, P. Pisa, Q.-J Zhang, M. Masucci, and R. Kiessling. 1994. Inlerleukin-10 pre-treatment protects target cells from tumor- and allo-specific cytotoxic T-cells and down-regulates HLA class I expression. J. Exp. Med. 180:2371.
9. Salazar-Onfray, F., M. Petersson, L. Franksson, M. Matsuda, T. Blankenstein, K. Kärre, and R. Kiessling. 1995. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J. Immunol. 154:6291.
10. Salazar-Onfray, F., J. Charo, M. Petersson, S. Freland, G. Noffz, Z. Qin, T. Blankenstein, H. G. Ljunggren, and R. Kiessling. 1997. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J. Immunol. 159:3195.
11. Kärre, K., H.-G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 319:675.
12. Powis, S. J., A. R. M. Townsend, E. V. Deverson, J. Bastin, G. W. Butcher, and J. C. Howard. 1991. Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter. Nature 354:528.
13. Attaya, M., S. Jameson, C. K. Martinez, E. Hermel, C. Aldrich, J. Forman, K. Fischer Lindahl, M. J. Bevan, and J. J. Monaco. 1992. Ham2 corrects the class I antigen-processing defect in RMA-S cells. Nature 355:647.
14. Pisa, P., E. Halapi, E. Pisa, E. K. Gerdin, C. Hising, A. Bucht, B. Gerdin, and R. Kiessling. 1992. Selective expression of interleukin 10, IFN-γ, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc. Natl. Acad. Sci. USA 89:7708.
15. Nakagomi, H., P. Pisa, E. K. Pisa, Y. Yamamoto, E. Halapi, K. Backlin, C. Juhlin, and R. Kiessling. 1995. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int. J. Cancer 63:366.
16. Kim, J., R. L. Modlin, R. L. Moy, S. M. Dubinett, T. McHugh, B. J. Nickoloff, and K. Uyemura. 1995. IL-10 production in cutaneous basal and squamous cell carcinomas. J. Immunol. 155:2240.
17. Lattime, E. C., M. J. Mastrangelo, O. Bagasra, W. Li, and D. Berd. 1995. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol. Immunother. 41:151.
18. Lattime, E. C., M. J. Mastrangelo, and D. Berd. 1994. Human metastatic melanoma lesions and cell lines express mRNA for IL-10. Proc. Am. Assoc. Cancer Res. 35:489.
19. Gotlieb, W. H., J. S. Abrams, J. M. Watson, T. J. Velu, J. S. Berek, and O. Martínez-Maza. 1992. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 4:385.
20. Chen, Q., V. Daniel, D. W. Maher, and P. Hersey. 1994. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer 56:755.
21. Gastl, G. A., J. S. Abrams, D. M. Nanus, R. Osterkamp, J. Silver, F. Liu, M. Chen, A. P. Albino, and N. H. J. Bander. 1993. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer 55:96.
22. Huang, M., J. Wang, P. Lee, S. Sharma, J. T. Mao, H. Meissner, K. Uyemura, R. Modlin, J. Wollman, and S. M. Dubinett. 1995. Human non-small lung cancer cells express a type 2 cytokine pattern. Cancer Res. 55:3847.
23. Benjamin, D., T. Knobloch, and M. Dayton. 1992. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphomas constitutively secrete large quantities of interleukin-10. Blood 80:1289.
24. Cikes, M., S. Friberg, Jr., and G. Klein. 1973. Progressive loss of H-2 antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas. J. Natl. Cancer Inst. 50:347.
25. Lupton, S. D., L. L. Brunton, V. A. Kalberg, and R. W. Overell. 1991. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol. Cell. Biol. 11:3374.
26. Blankenstein, T., Z. H. Qin, K. Uberla, W. Muller, H. Rosen, H. D. Volk, and T. Diamantstein. 1991. Tumor suppression after tumor cell-targeted TNF-α gene transfer. J. Exp. Med. 173:1047.
27. Shepherd, J. C., T. N. M. Schummacher, P. G. Ashton-Rickardt, S. Imaeda, H. L. Ploegh, C. A. Janeway, and S. Tonegawa. 1993. TAP1-dependent peptide translocation in vitro is ATP-dependent and peptide-selective. Cell 74:577.
28. Hunter, W. M., and F. C. Greenwood. 1962. Preparation of iodine-131-labeled human growth hormone of high specific activity. Nature 194:495.
29. Neefjes, J. J., F. Momburg, and G. J. Hämmerling. 1993. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 261:769.
30. Bergmann, C., S.A. Stohlmann and M. McMillan. 1993. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein. Eur. J. Immunol. 23:2777.
31. Rammensee, H. G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
32. Cikes, M. 1975. Antigenic changes in cultured murine lymphomas after retransplantation into syngenic hosts. J. Natl. Cancer Inst. 54:903.
33. Becker, S., R. Kiessling, N. Lee, and G. Klein. 1978. Modulation of sensitivity to NK cell lysis after in vitro explantation of a mouse lymphoma. J. Natl. Cancer Inst. 61:1495.
34. Petersson, M. G., K. Karre, M. Cochet, P. Kourilsky, and R. Kiessling. 1987. An active T-cell-independent mechanism enhances MHC class I transcription and expression on a mouse T-cell lymphoma in vivo. Cell. Immunol. 108:460.
35. Kiessling, R., E. Klein, and H. Wigzell. 1975. "Natural" killer cells in the mouse: cytotoxic cells with specificity for mouse Moloney leukemia cells: specificity and distribution according to genotype. Eur. J. Immunol. 5:112.
36. Ljunggren, H. G., N. J. Stam, C. Ohlen, J. J. Neefjes, P. Hoglund, M. T. Heemels, J. Bastin, T. N. Schumacher, A. Townsend, and K. Karre. 1990. Empty MHC class I molecules come out in the cold. Nature 346:476.
37. Franksson, L., E. George, S. Powis, G. Butcher, J. Howard, and K. Kärre. 1993. Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene. J. Exp. Med. 177:201.
38. Piontek, G. E., K. Taniguchi, H. G. Ljunggren, A. Grönberg, R. Kiessling, G. Klein, and K. Kärre. 1985. YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after IFN treatment or in vivo passage. J. Immunol. 135:4281.
39. Welsh, R. M., K. Karre, M. Hansson, L. A. Kunkel, and R. W. Kiessling. 1981. IFN-mediated protection of normal and tumor target cells against lysis by mouse NK cells. J. Immunol. 126:219.
40. Trinchieri, G., and D. Santoli. 1978. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells: enhancement of human NK cell activity by IFN and antagonistic inhibition of susceptibility of target cells to lysis. J. Exp. Med. 147:1314.
41. Sugita, K., J.-I. Miyazaki, E. Appella, and K. Ozato. 1987. Interferons increase transcription of a mayor histocompalibility class I gene via a 5′ IFN consensus sequence. Mol. Cell. Biol. 7:2625.
42. + T cells against the wild-type tumor: correlation with antigen-presentation capability. J. Exp. Med. 175:1423.
43. Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mulé, S. A. Rosenberg, and J. R. Bennink. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:265.
44. Rotem-Yehudar, R., S. Winograd, S. Sela, J. E. Coligan, and R. Ehrlich. 1994. Downregulation of peptide transporter genes in cell lines transformed with the highly oncogenic adenovirus 12. J. Exp. Med. 180:477.
45. Rotem-Yehudar, R., M. Groettrup, A. Soza, P. M. Kloetzel, and R. Ehrlich. 1996. LMP-associated proteolytic activities and TAP-dependent peptide transport for class I MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J. Exp. Med. 183:499.
46. Hill, A., P. Jugovic, I. York, G. Russ, J. Bennink, J. Yewdell, H. Ploegh, and D. Johnson. 1995. Herpes simplex virus turns off the TAP to evade host immunity. Nature 375:411.
47. Fruh, K., K. Ahn, H. Djaballah, P. Sempe, P. M. van Endert, R. Tampe, P. A. Peterson, and Y. Yang. 1995. A viral inhibitor of peptide transporters for antigen presentation. Nature 375:415.
48. Zeidler, R., G. Eissner, P. Meissner, S. Uebel, R. Tampe, S. Lazis, and W. Hammerschmidt. 1997. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 90:2390.
49. Yue, F. Y., R. Dummer, R. Geertsen, G. Hofbauer, E. Laine, S. Manolio, and G. Burg. 1997. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II, and ICAM-1 molecules. Int. J. Cancer 71:630.